Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-033/00
A61M-016/00
A61M-016/10
출원번호
US-0595108
(2006-11-10)
등록번호
US-8518457
(2013-08-27)
발명자
/ 주소
Miller, Christopher C.
Hole, Douglas R.
Murray, Bruce R
Perry, Bryan
출원인 / 주소
Pulmonox Technologies Corporation
인용정보
피인용 횟수 :
3인용 특허 :
112
초록▼
Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coi
Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
대표청구항▼
1. A method of treating excess mucus accumulation in a mammal's airway comprising: providing a pressurized source of nitric oxide containing gas; andadministering through inhalation a therapeutically effective amount of nitric oxide containing gas to a mammal exhibiting excess mucus accumulation in
1. A method of treating excess mucus accumulation in a mammal's airway comprising: providing a pressurized source of nitric oxide containing gas; andadministering through inhalation a therapeutically effective amount of nitric oxide containing gas to a mammal exhibiting excess mucus accumulation in the mammal's airway, wherein the nitric oxide containing gas is administered substantially coincident with the inspiration of the mammal, resulting in the flow of non-viscous liquids and mucus reduction. 2. The method of claim 1, further comprising the step of regulating a flow rate of the nitric oxide containing gas depending on the mammal's respiratory tidal volume. 3. The method of claim 2, wherein the concentration of nitric oxide gas in the mammal's airway ranges from about 160 ppm to about 220 ppm. 4. The method of claim 1, wherein the administration of the nitric oxide containing gas is timed according to a synchronous parameter of the mammal's respiratory cycle. 5. The method of claim 4, wherein the synchronous parameter is selected from a group consisting of rate of flow of gas directed toward the mammal's airway, pressure change at the initiation of a breath, the synchronous movement of the laryngeal, and the synchronous motion of the chest wall. 6. The method of claim 1, wherein the therapeutically effective amount of nitric oxide containing gas is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%. 7. The method of claim 1, wherein the therapeutically effective amount of nitric oxide containing gas is sufficient to effect mucolysis within thirty minutes. 8. The method of claim 1, wherein the mammal is a horse. 9. A method of treating excess mucus accumulation in a mammal's airway comprising: identifying a mammal exhibiting excess mucus accumulation;determining the severity of mucus accumulation in the mammal;providing a source of nitric oxide containing gas; andadministering through inhalation the nitric oxide containing gas using a distinct therapeutic profile corresponding to the severity of mucus accumulation in the mammal, resulting in the flow of non-viscous liquids and mucus reduction. 10. The method of claim 9, wherein the severity of mucus accumulation is scored from 0 to 5, with 5 indicating a most severe condition. 11. The method of claim 9, wherein the distinct therapeutic profile is selected from a pre-determined set of therapeutic profiles. 12. The method of claim 11, wherein the distinct therapeutic profile comprises therapeutic parameters selected from a group consisting of flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways. 13. The method of claim 9, wherein the mammal is a horse. 14. A method of treating excess mucus accumulation in a mammal's airway comprising: administering through inhalation a therapeutically effective amount of NO-releasing compounds to a mammal exhibiting excess mucus accumulation in the mammal's airway, resulting in the flow of non-viscous liquids and mucus reduction. 15. The method of claim 14, wherein the NO-releasing compounds is selected from a group consisting of S-nitrosothiols, S-nitroso-N-acetylpenicillamine, S-nitroso-L-cysteine, NONOates, nitroprusside, NO-ferredoxin, NO-heme complex, and nitrosoguanidine. 16. The method of claim 14, wherein the mammal is a horse. 17. The method of claim 14, wherein the therapeutically effective amount of NO-releasing compounds is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%. 18. The method of claim 14, wherein the therapeutically effective amount of NO-releasing compounds sufficient to effect mucolysis within thirty minutes. 19. A method of treating excess mucus accumulation in a mammal's airway comprising: identifying a mammal exhibiting excess mucus accumulation;determining the severity of mucus accumulation in the mammal; andadministering through inhalation NO-releasing compounds using a distinct therapeutic profile corresponding to the severity of mucus accumulation in the mammal, resulting in the flow of non-viscous liquids and mucus reduction. 20. The method of claim 19, wherein the NO-releasing compounds is selected from a group consisting of S-nitrosothiols, S-nitroso-N-acetylpenicillamine, S-nitroso-L-cysteine, NONOates, nitroprusside, NO-ferredoxin, NO-heme complex, and nitrosoguanidine. 21. The method of claim 19, wherein the severity of mucus accumulation is scored from 0 to 5, with 5 indicating a most severe condition. 22. The method of claim 19, wherein the distinct therapeutic profile is selected from a pre-determined set of therapeutic profiles. 23. The method of claim 19, wherein the mammal is a horse. 24. The method of claim 19, wherein the therapeutically effective amount of NO-releasing compounds is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%. 25. The method of claim 19, wherein the therapeutically effective amount of NO-releasing compounds sufficient to effect mucolysis within thirty minutes.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (112)
Bathe Duncan P. L. ; Montgomery Frederick J., Accurate dose nitric oxide pulse delivery device with monitoring and alarms.
Kamibayashi, Masato; Sawamoto, Jiro; Motoyama, Shinji; Endo, Fumiaki, Apparatus for artificial kidney, quality evaluating device for dialyzing fluid and dialyzing means using the same, and fluid circuit.
Ryschka Martin (Stockelsdorf DEX) Falb Wolfgang (Krumesse DEX) Bttner Peter (Stockelsdorf DEX) Wallroth Carl-Friedrich (Lbeck DEX), Arrangement for adding liquid anesthetic to the respiratory gas supplied to a patient.
Saavedra Joseph E. (Thurmont MD) Keefer Larry K. (Bethesda MD) Roller Peter P. (Rockville MD) Akamatsu Miki (Rockville MD), Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of trea.
Saavedra Joseph E. ; Keefer Larry K. ; Roller Peter P. ; Akamatsu Miki, Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same.
Olsson Sven-Gunnar (Arloev SEX) Rydgren Goeran (Bunkeflostrand SEX) Larsson Anders (Kaevlinge SEX) Brauer Stefan (Sodra Sandby SEX) Linge Anders (Kaevlinge SEX), Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject.
Fitzhugh, Anthony L.; Cafferata, Robert; Keefer, Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Keefer Larry K. (Bethesda MD) Hrabie Joseph A. (Frederick MD), Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric o.
Vodovotz, Yoram; Gage, Frederick A., Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use.
Cegielski Michael J. (2404 Temescal Norco CA 91760) van den Berg Teunis T. (24699 Moondshadow Dr. Marino Valley CA 92387), Method and apparatus for selectively mixing gases.
Weinstein, Robert E., Method and device for organizing and coordinating the combined use of liquid medications for continuous nebulization for the treatment of respiratory disorders.
Stossel Thomas P. (Belmont MA) Lind Stuart E. (Wellesley MA) Janmey Paul A. (Arlington MA), Method for reducing the viscosity of purulent airway contents in the respiratory tract comprising administering actin-bi.
Ghio Andrew J. ; Piantadcsi Claude A. ; Kennedy Thomas P., Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers.
Bathe Duncan P. L. (Madison WI) Kohlmann Thomas S. (McFarland WI) Pinkert John R. (Madison WI) Tham Robert Q. (Middleton WI), Nitric oxide delivery system.
Jeffrey E. Thomas, Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal.
Wink ; Jr. David A. ; Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Hanbauer Ingeborg ; Grisham Matthew B. ; Granger Daniel Neil, Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury.
Joseph E. Saavedra ; Larry K. Keefer ; Peter P. Roller ; Miki Akamatsu, Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same.
Hrabie, Joseph A.; Keefer, Larry K.; Arnold, Ernst V., Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie Joseph A. ; Keefer Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Hrabie, Joseph A.; Keefer, Larry K., Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Nitric oxide-releasing compounds to sensitive cancerous cells to chemotherapeutic agents.
Arnold, Ernst V.; Keefer, Larry K.; Hrabie, Joseph A., Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same.
Fitzhugh Anthony L. ; Cheng Peiwen ; Saavedra Joseph ; Cafferata Robert ; Hendriks Marc,NLX ; Keefer Larry K. ; Tedeschi Eugene ; Verhoeven Michel L. P. M.,NLX, Nitric oxide-releasing metallic medical devices.
Fitzhugh, Anthony L.; Cheng, Peiwen; Saavedra, Joseph; Cafferata, Robert; Hendriks, Marc; Keefer, Larry K.; Tedeschi, Eugene; Verhoeven, Michel I. P. M., Nitric oxide-releasing metallic medical devices.
Kim,Hyung Min; You,HyungJa; Seo,Sang Bong, Pharmaceutical composition for increasing the production of nitric oxide and IFN-γ, and process for preparation thereof.
Sheu Lien-Lung (Scotch Plains NJ) Ramachandran Ramakrishnan (Allendale NJ) Galica Theodore R. (Glen Gardner NJ), Process for the purification of nitric oxide.
Stamler Jonathan (Chapel Hill NC) Loscalzo Joeseph (Dedham MA) Slivka Adam (Randolph MA) Simon Daniel (Waban MA) Brown Robert (Natick MA) Drazen Jeffrey (Winchester MA), S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof.
Frostell Claes G. (Vallingby SEX) Hedenstierna Goran (Djursholm SEX) Hogman Marieann E. (Alunda MA SEX) Loscalzo Joseph (Dedham MA) Stamler Jonathan S. (Boston MA), Systemic effects of nitric oxide inhalation.
Mitchell James B. (Damascus MD) Russo Angelo (Bethesda MD) Krishna Murali C. (Derwood MD) Wink ; Jr. David A. (Hagerstown MD) Liebmann James E. (Albuquerque NM), Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents.
Korthuis Ronald J. (Shreveport LA) Kong Lipu (Shreveport LA) Keefer Larry K. (Bethesda MD), Use of nitric oxide-releasing agents for reducing metastasis risk.
Mitchell James B. ; Russo Angelo ; Krishna Murali C. ; Wink ; Jr. David A. ; Liebmann James E., Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers.
Jonathan S. Stamler ; Claude A. Piantadosi ; Mark W. Dewhirst, Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.